Osteoarthritis and Degenerative Spine Pathologies

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 871-888

  Kesson, Kristina ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60249095932     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50053-4     Document Type: Chapter

References (129)

1. Lohmander L.S. Markers of altered metabolism in osteoarthritis. J. Rheumatol. 2004, 31:28-35.
2. Petersson I.F. Occurrence of osteoarthritis of the peripheral joints in European populations. Ann. Rheum. Dis. 1996, 55:659-661.
3. Danielsson L.G. Incidence and prognosis of coxarthrosis. Acta. Orthop. Scand. 1964, 42(Suppl 66):61-114.
4. Spector T.D., Dacre J.E., Harris P.A., Huskisson E.C. Radiological progression of osteoarthritis: an 11 year follow up study of the knee. Ann. Rheum. Dis. 1992, 51:1107-1110.
5. Westacott C.I., Webb G.R., Warnock M.G., Sims J.V., Elson C.J. Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum. 1997, 40:1282-1291.
6. Cooper C., Campbell L., Byng P., Croft P., Coggon D. Occupational activity and the risk of hip osteoarthritis. Ann. Rheum. Dis. 1996, 55:680-682.
7. Vingard E. Osteoarthrosis of the knee and physical load from occupation. Ann. Rheum. Dis. 1996, 55:677-679.
8. Roos H., Lindberg H., Gardsell P., Lohmander L.S., Wingstrand H. The prevalence of gonarthrosis and its relation to meniscectomy in former soccer players. Am. J. Sports Med. 1994, 22:219-222.
9. Vikkula M., Palotie A., Ritvaniemi P., Ott J., Ala-Kokko L., Sievers U., Aho K., Peltonen L. Early-onset osteoarthritis linked to the type II procollagen gene. Detailed clinical phenotype and further analyses of the gene. Arthritis Rheum. 1993, 36:401-409.
10. Kjellgren J.H., Jeffrey M., Ball J. Atlas of standard radiographs. The Epidemiology of Chronic Rheumatism 1963, O.B. Scientific (Ed.).
11. Ahlback S. Osteoarthrosis of the knee. A radiographic investigation. Acta. Radiol. Diagn. (Stockh) 1968, (Suppl 277):7-72.
12. Dieppe P., Cushnaghan J., Young P., Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann. Rheum. Dis. 1993, 52:557-563.
13. McAlindon T.E., Watt I., McCrae F., Goddard P., Dieppe P.A. Magnetic resonance imaging in osteoarthritis of the knee: correlation with radiographic and scintigraphic findings. Ann. Rheum. Dis. 1991, 50:14-19.
14. Blackburn W.D., Chivers S., Bernreuter W. Cartilage imaging in osteoarthritis. Semin Arthritis. Rheum. 1996, 25:273-281.
15. Recht M.P., Resnick D. Magnetic resonance imaging of articular cartilage: an overview. Top Magn. Reson. Imaging 1998, 9:328-336.
16. Dieppe P.A., Cushnaghan J., Shepstone L. The Bristol 'OA500' study: progression of osteoarthritis (OA) over 3 years and the relationship between clinical and radiographic changes at the knee joint. Osteoarthritis Cartilage 1997, 5:87-97.
17. Burstein D., Velyvis J., Scott K.T., Stock K.W., Kim Y.J., Jaramillo D., Boutin R.D., Gray M.L. Protocol issues for delayed Gd(DTPA)(2-)-enhanced MRI (dGEMRIC) for clinical evaluation of articular cartilage. Magn. Reson. Med. 2001, 45:36-41.
18. Tiderius C.J., Olsson L.E., Leander P., Ekberg O., Dahlberg L. Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) in early knee osteoarthritis. Magn. Reson. Med. 2003, 49:488-492.
19. Tiderius C.J., Svensson J., Leander P., Ola T., Dahlberg L. dGEMRIC (delayed gadolinium-enhanced MRI of cartilage) indicates adaptive capacity of human knee cartilage. Magn. Reson. Med. 2004, 51:286-290.
20. Lane N.E. Physical activity at leisure and risk of osteoarthritis. Ann. Rheum. Dis. 1996, 55:682-684.
21. Parfitt A.M. The physiological and clinical significance of bone histomorphometric data. Bone Histomorphometry. Techniques and Interpretations 1993, 143-223. CRC Press, Boca Raton, FL. R.R. (Ed.).
22. Rodan G.A., Martin T.J. Role of osteoblasts in homonal control of bone resorption - a hypothesis. Calcif. Tissue. Int. 1981, 33:349-351.
23. Price P.A. Vitamin K-dependent formation of bone G1a protein (osteocalcin) and its function. Vitam. Horm. 1985, 42:65-108.
24. Eyre D.R. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta. Orthop. Scand. Suppl. 1995, 266:166-170.
25. Akesson K. Biochemical markers of bone turnover. A review. Acta. Orthop. Scand. 1995, 66:376-386.
26. Delmas P.D. Biochemical markers of bone turnover. Acta. Orthop. Scand. Suppl. 1995, 266:176-182.
27. Dequeker J. The relationship between osteoporosis and osteoarthritis. Clin. Rheum. Dis. 1985, 11:271-296.
28. Gevers G., Dequeker J., Geusens P., Verstraeten A., Vanderschueren D. Serum bone G1a protein (osteocalcin) and other markers of bone mineral metabolism in postmenopausal osteoporosis and osteoarthritis. J. Orthop. Rheum. 1988, 1:22-27.
29. Geusens P., Vanderschueren D., Verstraeten A., Dequeker J., Devos P., Bouillon R. Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis. Calcif. Tissue Int. 1991, 49:168-173.
30. Garnero P., Piperno M., Gineyts E., Christgau S., Delmas P.D., Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 2001, 60:619-626.
31. Bruyere O., Collette J.H., Ethgen O., Rovati L.C., Giacovelli G., Henrotin Y.E., Seidel L., Reginster J.Y. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J. Rheumatol. 2003, 30:1043-1050.
32. Naitou K., Kushida K., Takahashi M., Ohishi T., Inoue T. Bone mineral density and bone turnover in patients with knee osteoarthritis compared with generalized osteoarthritis. Calcif. Tissue Int. 2000, 66:325-329.
33. Raymaekers G., Aerssens J., Van den Eynde R., Peeters J., Geusens P., Devos P., Dequeker J. Alterations of the mineralization profile and osteocalcin concentrations in osteoarthritic cortical iliac crest bone. Calcif. Tissue Int. 1992, 51:269-275.
34. Campion G.V., Delmas P.D., Dieppe P.A. Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br. J. Rheumatol. 1989, 28:393-398.
35. Poole A.R., Ionescu M., Swan A., Campion G.V., Rosenberg L.C., Dieppe P. Analysis of cartilage and bone molecules and hyaluronic acid in synovial fluid and peripheral bloods of patients with arthritis. Transactions of the combined meeting of the Orthopaedic Research Societies 1991, University of Calgary Printing Service, Banff, Alberta.
36. Mattei J.P., Ferrera V., Boutsen Y., Franceschi J.P., Botti D., De Boissezon C., Kaphan G., Roux H. Serum and synovial fluid osteocalcin in rheumatic diseases. Int. J. Clin. Pharmacol. Res. 1992, 12:103-107.
37. Sharif M., George E., Dieppe P.A. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. Arthritis Rheum. 1995, 38:78-81.
38. Fairney A., Patel K.V., Hollings N.P., Seifert M.H. Abnormal osteocalcin binding in rheumatoid arthritis. Ann. Rheum. Dis. 1990, 49:229-230.
39. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 1996, 11:337-349.
40. Peel N.F., Barrington N.A., Blumsohn A., Colwell A., Hannon R., Eastell R. Bone mineral density and bone turnover in spinal osteoarthrosis. Ann. Rheum. Dis. 1995, 54:867-871.
41. Mansell J.P., Tarlton J.F., Bailey A.J. Biochemical evidence for altered subchondral bone collagen metabolism in osteoarthritis of the hip. Br. J. Rheumatol. 1997, 36:16-19.
42. Risteli J., Niemi S., Kauppila S., Melkko J., Risteli L. Collagen propeptides as indicators of collagen assembly. Acta. Orthop. Scand. Suppl. 1995, 266:183-188.
43. Charles P., Mosekilde L., Risteli L., Risteli J., Eriksen E.F. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner. 1994, 24:81-94.
44. Scariano J.K., Garry P.J., Montoya G.D., Duran-Valdez E., Baumgartner R.N. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand. J. Clin. Lab. Invest. 2002, 62:237-243.
45. Tahtela R., Seppanen J., Laitinen K., Katajarnaki A., Risteli J., Valimaki M.J. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos. Int. 2005, 16:1109-1116.
46. Schmidt-Rohlfing B., Thomsen M., Niedhart C., Wirtz D.C., Schneider U. Correlation of bone and cartilage markers in the synovial fluid with the degree of osteoarthritis. Rheumatol. Int. 2002, 21:193-199.
47. Wilkinson J.M., Stockley I., Harmer A.J., Barrington N.A., Eastell R. Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J. Orthop. Res. 2003, 21:529-534.
48. Eyre D.R. The collagens of articular cartilage. Semin. Arthritis Rheum. 1991, 21:2-11.
49. Delmas P.D., Eastell R., Gamero P., Seibel M.J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos. Int. 2000, 11(Suppl 6):S2-S17.
50. Garnero P., Mulleman D., Munoz F., Sornay-Rendu E., Delmas P.D. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J. Bone Miner. Res. 2003, 18:1789-1794.
51. Gerdhem P., Ivaska K.K., Alatalo S.L., Halleen J.M., Hellman J., Isaksson A., Pettersson K., Vaananen H.K., Akesson K., Obrant K.J. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J. Bone Miner. Res. 2004, 19:386-393.
52. Garnero P., Landewe R., Boers M., Verhoeven A., Van Der Linden S., Christgau S., Van Der Heijde D., Boonen A., Geusens P. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002, 46:2847-2856.
53. Hermann J., Mueller T., Fahrleitner A., Dimai H.P. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab. Clin. Exp. Rheumatol. 2003, 21:473-476.
54. Takahashi M., Kushida K., Hoshino H., Suzuki M., Sano M., Miyamoto S., Inoue T. Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Ann. Rheum. Dis. 1996, 55:324-327.
55. Robins S.P., Stewart P., Astbury C., Bird H.A. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. Ann. Rheum. Dis. 1986, 45:969-973.
56. Black D., Duncan A., Robins S.P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal. Biochem. 1988, 169:197-203.
57. Seibel M.J., Duncan A., Robins S.P. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J. Rheumatol. 1989, 16:964-970.
58. Thompson P.W., Spector T.D., James I.T., Henderson E., Hart D.J. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. Br. J. Rheumatol. 1992, 31:759-761.
59. Astbury C., Bird H.A., McLaren A.M., Robins S.P. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Br. J. Rheumatol. 1994, 33:11-15.
60. Graverand M.P., Tron A.M., Ichou M., Dallard M.C., Richard M., Uebelhart D., Vignon E. Assessment of urinary hydroxypyridinium cross-links measurement in osteoarthritis. Br. J. Rheumatol. 1996, 35:1091-1095.
61. MacDonald A.G., McHenry P., Robins S.P., Reid D.M. Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis. Br. J. Rheumatol. 1994, 33:16-19.
62. Garnero P., Rousseau J.C., Delmas P.D. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 2000, 43:953-968.
63. Bettica P., Cline G., Hart D.J., Meyer J., Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum. 2002, 46:3178-3184.
64. Sinigraglia L., Varenna M., Binelli L., Bartucci F., Arrigoni M., Ferrara R., Abbiati G. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 1995, 54:144-147.
65. Yaziji H., Janckila A.J., Lear S.C., Martin A.W., Yam L.T. Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Am. J. Clin. Pathol. 1995, 104:397-402.
66. Oddie G.W., Schenk G., Angel N.Z., Walsh N., Guddat L.W., de Jersey J., Cassady A.I., Hamilton S.E., Hume D.A. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 2000, 27:575-584.
67. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Vaananen H.K. Tartrate-resistant acid phosphatase 5b; a novel serum marker of bone resorption. J. Bone Miner. Res. 2000, 15:1337-1345.
68. Halleen J.M., Ylipahkala H., Alatalo S.L., Janckila A.J., Heikkinen J.E., Suominen H., Cheng S., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif. Tissue Int. 2002, 71:20-25.
69. Halleen J.M. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res. 2003, 23:1027-1029.
70. Janckila A.J., Neustadt D.H., Nakasato Y.R., Halleen J.M., Hentunen T., Yam L.T. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin. Chim. Acta. 2002, 320:49-58.
71. Oldberg A., Franzen A., Heinegard D. The primary structure of a cell-binding bone sialoprotein. J. Biol. Chem. 1988, 263:19430-19432.
72. Seibel M.J., Woitge H.W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., Armbruster F.P., Ziegler R. Serum immunore active bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J. Clin. Endocrinol. Metab. 1996, 81:3289-3294.
73. Conrozier T., Shan C., Saxen T., Mathieu P., Pipemo M., Vignon E. Serum level of bone sialoprotein correlates with subchondral bone changes in hip osteoarthritis. Osteoarthritis Cartilage 1997, 5(Suppl):49.
74. Petersson I.F., Boegard T., Dahlstrom J., Svensson B., Heinegard D., Saxne T. Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. Osteoarthritis Cartilage 1998, 6:33-39.
75. Petersson I.F., Boegard T., Svensson B., Heinegard D., Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br. J. Rheumatol. 1998, 37:46-50.
76. Poole A.R., Dieppe P. Biological markers in rheumatoid arthritis. Semin. Arthritis. Rheum. 1994, 23:17-31.
77. Poole A.R., Ionescu M., Swan A., Dieppe P.A. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J. Clin. Invest. 1994, 94:25-33.
78. Lohmander L.S., Dahlberg L., Ryd L., Heinegard D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 1989, 32:1434-1442.
79. Lohmander L.S., Saxne T., Heinegard D.K. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann. Rheum. Dis. 1994, 53:8-13.
80. Dahlberg L., Ryd L., Heinegard D., Lohmander L.S. Proteoglycan fragments in joint fluid. Influence of arthrosis and inflammation. Acta. Orthop. Scand. 1992, 63:417-423.
81. Thonar E.J., Lenz M.E., Klintworth G.K., Caterson B., Pachman L.M., Glickman P., Katz R., Huff J., Kuetner K.E. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum. 1985, 28:1367-1376.
82. Campion G.V., McCrae F., Schnitzer T.J., Lenz M.E., Dieppe P.A., Thonar E.J. Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. Arthritis Rheum. 1991, 34:1254-1259.
83. Bleasel J.F., Poole A.R., Heinegard D., Saxne T., Holderbaum D., Ionescu M., Jones P., Moskowitz R.W. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum. 1999, 42:39-45.
84. Ratcliffe A., Flatow E.L., Roth N., Saed-Nejad F., Bigliani L.U. Biochemical markers in synovial fluid identify early osteoarthritis of the glenohumeral joint. Clin. Orthop. 1996, 330:45-53.
85. Sharif M., Osborne D.J., Meadows K., Woodhouse S.M., Colvin E.M., Shepstone L., Dieppe P.A. The relevance of chondroitin and keratan sulphate markers in normal and arthritic synovial fluid. Br. J. Rheumatol. 1996, 35:951-957.
86. Spector T.D., Woodward L., Hall G.M., Hammond A., Williams A., Butler M.G., James I.T., Hart D.J., Thompson P.W., Scott D.L. Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases. Ann. Rheum. Dis. 1992, 51:1134-1137.
87. Sharif M., George E., Shepstone L., Knudson W., Thonar E.J., Cushnaghan J., Dieppe P. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum. 1995, 38:760-767.
88. Lohmander L.S., Ionescu M., Jugessur H., Poole A.R. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum. 1999, 42:534-544.
89. Slater R.R., Bayliss M.T., Lachiewicz P.F., Visco D.M., Caterson B. Monoclonal antibodies that detect biochemical markers of arthritis in humans. Arthritis Rheum. 1995, 38:655-659.
90. Ratcliffe A., Grelsamer R.P., Kiernan H., Saed-Nejad F., Visco D. High levels of aggrec an aggregate components are present in synovial fluids from human knee joints with chronic injury or osteoarthrosis. Acta. Orthop. Scand. Suppl. 1995, 266:111-115.
91. Lewis S., Crossman M., Flannelly J., Belcher C., Doherty M., Bayliss M.T., Mason R.M. Chondroitin sulphation patterns in synovial fluid in osteoarthritis subsets. Ann. Rheum. Dis. 1999, 58:441-445.
92. Ishiguro N., Ito T., Ito H., Iwata H., Jugessur H., Ionescu M., Poole A.R. Relationship of matrix metalloprote inases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum. 1999, 42:129-136.
93. Hedborn E., Antonsson P., Hjerpe A., Aeschlimann D., Paulsson M., Rosa-Pimentel E., Sommarin Y., Wendel M., Oldberg A., Heinegard D. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J. Biol. Chem. 1992, 267:6132-6136.
94. Saxne T., Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br. J. Rheumatol. 1992, 31:583-591.
95. Petersson I.F., Sandqvist L., Svensson B., Saxne T. Cartilage markers in synovial fluid in symptomatic knee osteoarthritis. Ann. Rheum. Dis. 1997, 56:64-67.
96. Vilim V., Vytasek R., Olejarova M., Machacek S., Gatterova J., Prochazka B., Kraus V.B., Pavelka K. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001, 9:612-618.
97. Sharif M., Saxne T., Shepstone L., Kirwan J.R., Elson C.J., Heinegard D., Dieppe P.A. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br. J. Rheumatol. 1995, 34:306-310.
98. Conrozier T., Saxne T., Fan C.S., Mathieu P., Tron A.M., Heinegard D., Vignon E. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann. Rheum. Dis. 1998, 57:527-532.
99. Hakala B.E., White C., Recklies A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 1993, 268:25803-25810.
100. Johansen J.S., Jensen H.S., Price P.A. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. 1993, 32:949-955.
101. Johansen J.S., Hvolris J., Hansen M., Backer V., Lorenzen I., Price P.A. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br. J. Rheumatol. 1996, 35:553-559.
102. Volck B., Johansen J.S., Stoltenberg M., Garbarsch C., Price P.A., Ostergaard M., Ostergaard K., Lovgreen-Nielsen P., Sonne-Holm S., Lorenzen I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001, 9:203-214.
103. Shinmei M., Kobayashi T., Yoshihara Y., Samura A. Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. J. Rheumatol. 1995, 43(Suppl.):78-81.
104. Lohmander L.S., Yoshihara Y., Roos H., Kobayashi T., Yamada H., Shinmei M. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J. Rheumatol. 1996, 23:1765-1769.
105. Kobayashi T., Yoshihara Y., Samura A., Yamada H., Shinmei M, Roos H., Lohmander L.S. Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis. Ann. Rheum. Dis. 1997, 56:500-503.
106. Kobayashi T., Yoshihara Y., Yamada H., Fujikawa K. Procollagen IIC-peptide as a marker for assessing mechanical risk factors of knee osteoarthritis: effect of obesity and varus alignment. Ann. Rheum. Dis. 2000, 59:982-984.
107. Sugiyama S., Itokazu M., Suzuki Y., Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann. Rheum. Dis. 2003, 62:27-32.
108. Nelson F., Dahlberg L., Laverty S., Reiner A., Pidoux I., Ionescu M., Fraser G.L., Brooks E., Tanzer M., Rosenberg L.C., Dieppe P., Poole A. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J. Clin. Invest. 1998, 102:2115-2125.
109. Gamero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., Delmas P.D. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002, 46:2613-2624.
110. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., Rosenquist C., Qvist P. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
111. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 2003, 48:3130-3139.
112. Matyas J.R., Atley L., Ionescu M., Eyre D.R., Poole A.R. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum. 2004, 50:543-552.
113. Murphy G. Matrix metalloproteinases and their inhibitors. Acta. Orthop. Scand. 1995, 266(Suppl.):55-60.
114. Lohmander L.S., Hoerrner L.A., Lark M.W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993, 36:181-189.
115. Chevalier X., Conrozier T., Gehrmann M., Claudepierre P., Mathieu P., Unger S., Vignon E. Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage 2001, 9:300-307.
116. Dahlberg L., Friden T., Roos H., Lark M.W., Lohmander L.S. A longitudinal study of cartilage matrix metabolism in patients with cruciate ligament rupture-synovial fluid concentrations of aggrecan fragments, stromelysin-1 and tissue inhibitor of metalloproteinase-1. Br. J. Rheumatol. 1994, 33:1107-1111.
117. Thonar E.J., Glant T. Serum keratan sulfate-a marker of predisposition to polyarticular osteoarthritis. Clin. Biochem. 1992, 25:175-180.
118. Buckwalter J.A. Aging and degeneration of the human intervertebral disc. Spine 1995, 20:1307-1314.
119. Pokharma H.K., Phillips F.M. Collagen crosslinks in human lumbar intervertebral disc aging. Spine 1998, 23:1645-1648.
120. Kang J.D., Stefanovic-Racic M., McIntyre L.A., Georgescu H.I., Evans C.H. Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Contributions of nitric oxide, interleukins, prostaglandin E2, and matrix metalloproteinases. Spine 1997, 22:1065-1073.
121. Duance V.C., Crean J.K., Sims T.J., Avery N., Smith S., Menage J., Eisenstein S.M., Roberts S. Changes in collagen cross-linking in degenerative disc disease and scoliosis. Spine 1998, 23:2545-2551.
122. Sztrolovics R., Alini M, Mort J.S., Roughley P.J. Age-related changes in fibromodulin and lumican in human intervertebral discs. Spine 1999, 24:1765-1771.
123. Roberts S., Caterson B., Menage J., Evans E.H., Jaffray D.C., Eisenstein S.M. Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc. Spine 2000, 25:3005-3013.
124. Kuiper J.I., Verbeek J.H., Frings-Dresen M.H., Ikkink A.J. Keratan sulfate as a potential biomarker of loading of the intervertebral disc. Spine 1998, 23:657-663.
125. El Miedany Y.M., Mehanna A.N., El Baddini M.A. Altered bone mineral metabolism in patients with osteoarthritis. Joint Bone Spine 2000, 67:521-527.
126. Garnero P., Sornay-Rendu E., Arlot M., Christiansen C., Delmas P.D. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum. 2004, 50:3137-3144.
127. Iwamoto J., Takeda T. Effect of surgical treatment on physical activity and bone resorption in patients with neurogenic intermittent claudication. J. Orthop. Sci. 2002, 7:84-90.
128. Pluijm S.M., van Essen H.W., Bravenboer N., Uitterlinden A.G., Smit J.H., Pols H.A., Lips P. Collagen type I alphal Spl polymorphism, osteoporosis, and intervertebral disc de generation in older men and women. Ann. Rheum. Dis. 2004, 63:71-77.
129. Otterness I.G., Swindell A.C., Zimmerer R.O., Poole A.R., Ionescu M., Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000, 8:180-185.